Background: Elderly patients with advanced non-small-cell lung cancer (NSCLC) may derive similar benefit from platinum-based chemotherapy as younger patients. Quality of life (QoL) and comprehensive geriatric assessment (CGA) is often advocated to assess benefits and risks.
Platinum-based combination chemotherapy is considered standard care for advanced NSCLC. Single-agent treatment is often recommended for elderly patients [9] [10] [11] [12] [13] [14] ; however, subset analysis from several platinum-based trials suggest similar efficacy in older patients, with an acceptable increase in toxicity [6] [7] [8] . To date, no prospective randomized trials with platinum-based combination regimens in elderly NSCLC patients have been published.
Our thoughts while conceiving the trial were that gemcitabine and paclitaxel have clearly different toxicity profiles. The first causes more fatigue flu-like symptoms and myelosuppression, while the other causes more neurotoxicities. Which of these toxic effects would have the most profound original article impact on patient's life? Choosing to compare two combination treatments allows for a differentiation of effects of toxicity on quality of life (QoL) (the primary end point) while maintaining similar survival profiles in both treatment arms (although a formal comparative study has not been carried out in the elderly population).
To estimate the benefits and risks of cancer treatment, it is important to consider the patients' life expectancy and functional reserve. In elderly patients, a comprehensive geriatric assessment (CGA) is often advocated to assess these benefits and risks [15] , as it adds substantial information to performance score (PS) [16] . Therefore, the dominant role of PS as the only marker of functional status in elderly patients has been questioned [16] . CGAs carried out in NSCLC patients are scarce [17, 18] . One major limitation of a CGA is its time-consuming nature. Thus, rapid screening instruments have been developed such as the Groningen Frailty Indicator (GFI) [19, 20] .
Remarkably little is known about QoL during and after chemotherapy in older NSCLC patients, whereas in this group, QoL should be paramount, as they may prefer quality above quantity of life [18, 21, 22] .
We conducted a randomized phase III trial to test which of two commonly used platinum-based chemotherapy regimens is associated with the greatest increase in QoL scores. A CGA was carried out to evaluate whether it can be used as a tool to predict which patients benefit from chemotherapy in terms of QoL and which patients experience toxicity. The underlying structures of baseline QoL and CGA and their prognostic value were also studied.
patients and methods

eligibility criteria
Patients were ‡70 years of age with pathologically confirmed inoperable stage III-IV NSCLC. Other inclusion criteria were World Health Organization PS of two or less; adequate bone marrow, liver and renal function (creatinine clearance ‡40 ml/min); measurable disease according to RECIST [23] . Exclusion criteria included active uncontrolled infections, CNS metastases, pretreatment sensory peripheral neuropathy ‡grade 1 according to National Cancer Institute of Canada Common Toxicity Criteria (CTC) and unstable cardiac conditions. Approval by the institutional review board at each center was required. Written informed consent was obtained from all patients.
treatment plan
A maximum of 4 three-week cycles of carboplatin-gemcitabine (CG) or carboplatin-paclitaxel (CP) was randomly assigned to patients using the minimization technique stratificating for PS, extent of disease and institution. The study design is depicted in Figure 1 .
Carboplatin was administered at an area under the concentration-time curve of 5 mg/ml/min i.v. on day 1 and either gemcitabine 1250 mg/m2 i.v. on days 1 and 8 or paclitaxel 175 mg/m2 i.v. at day 1.
Chemotherapy dose modification and stopping rules are shown in supplemental Table S1 (available at Annals of Oncology online). Darbepoetin alpha (150 lg s.c. once weekly) was started at a hemoglobin level <6.8 mmol/l (11 g/dl), and continued until 4 weeks after treatment or until the hemoglobin level exceeded 8.1 mmol/l (13 g/dl).
Tumor response was evaluated after two and four cycles, at week 18 and every 6 weeks until disease progression. Toxicity was assessed weekly using the NCI-CTC version 2. From the NCI-CTC list, we took issues regarding neuropsychiatric toxicity. That was cognitive disturbances, confusion, delusions, depressed levels of consiousness, hallucinations and insomnia, memory loss, mood alteration-anxiety, agitations, mood alterationsdepression, mood alterations-euphoria and personality behavior. geriatric assessments. Before start of treatment, a CGA was administered by a trained nurse. The CGA included the evaluation of comorbidity according to Charlson et al. [24] and the Cumulative Illness Rating Scale-Geriatrics (CIRS-G) [25] ; functional status by activities of daily living (ADL) [26] , instrumental activities of daily living (IADL) [27] and the Timed Up and Go test (TUG) [28] ; cognition with Mini Mental State Examination (MMSE) [29] ; depression with the Geriatric Depression Scale (GDS)-15 [30] ; affect with Positive and Negative Affect Schedule (PANAS) [31] ; and frailty with the GFI [19, 20] .
During treatment and follow-up, a mini geriatric assessment (MGA) was carried out on days 1 and 8 of each cycle, at weeks 12, 15 and 18. MGA included assessments of neuropsychiatric toxicity, TUG and PANAS and QoL.
statistical considerations
Sample size. Primary end point was the change in global QoL from baseline to week 18 (6 weeks after the end of treatment). The sample size was calculated based on the comparison between treatment arms of the change in the global QoL score between baseline and week 18. The study was Annals of Oncology original article planned to have a 90% power to detect an effect size of 0.5 between the two arms (at the 0.05 significance level) with 172 patients, 86 in each arm. This would also allow 80% power to detect differences in survival that could be characterized by a ratio in the hazards of death of 1.5 if most patients would be followed until death. No interim analysis was foreseen.
Baseline comparisons. Patient characteristics assessed at baseline were compared between the two treatment groups using Fisher's exact and Kruskal-Wallis tests where appropriate.
QoL analysis. The primary end point was compared between arms by means of a Mann-Whitney test. Only patients for whom baseline and week 18 global QoL scores were available were included in this analysis. No imputation was carried out. To account for patients not completing QoL at week 18, a linear mixed-effects model was constructed in which the within patient global QoL scores (reported during treatment and until week 18) were tested for a difference between treatment arms, while adjusting for gender, age, extent of disease, PS at baseline, weight loss before treatment and baseline global QoL (modeled as fixed effects).
A QoL responder was defined as a patient who had had an improvement of ‡10 points as compared with baseline on the global QoL scale [32] .
Analysis of survival. The effect of treatment on survival and quality-adjusted survival was estimated using Kaplan-Meier curves [33] and compared using log-rank tests stratified for PS. Overall survival was calculated as the time since randomization until death or last follow-up. Progression-free survival (PFS) was calculated as the time since randomization until progression, death or last follow-up. Quality-adjusted survival was calculated as the survival time since randomization until death weighted by their global QoL for each assessment period. Patients were censored if they stopped returning QoL assessments or were lost to follow-up.
Analysis of CGA-QoL and survival. Associations of CGA and QoL scores with overall survival were studied and included in total 16 test scores (9 baseline CGA scores, 1 QLQ-C30 global, 5 other QoL domains and 1 baseline PS). Due to the correlated nature of the CGA and QoL items, a principal component (PC) transformation was carried out using the correlation matrix to determine the number of orthogonal dimensions explaining the variation in the questionnaire scores. TUG was excluded with >20% missing scores, five patients with poor completion of the CGA ( ‡10 items missing) are excluded. Six CGA items (from four patients) were imputed using the item medians. The variance explained by each PC is examined, and the first PC is tested for association with overall survival using a Cox proportional hazards model.
Analysis of CGA-QoL and toxicity. An exploratory analysis was undertaken to investigate whether items of the CGA and the QLQ-C30 dimensions could be used as predictive factors for toxicity end points. Logistic regression models were used to evaluate which of the CGA summary scores were most associated with the toxicity end points, while adjusting for age, gender and extent of disease. No imputation was carried out. To account for multiple testing, the significance level was set to 0.01 for the exploratory analysis. Table 1 ). The slightly lower proportion of octogenarians and those with >10% baseline weight loss favoring the CG arm were not statistically different between treatment arms. Percentage of patients completing all four cycles was 64% and 65% in the CG and CP arms, respectively. Per-protocol dose reductions were 30% and 9% of the patients in the CG and CP arm (P < 0.001), respectively. Dose delays occurred in 15% and 3% of the CG and CP patients (P = 0.008). The main reasons for early treatment discontinuation in the CG and CP arm were disease progression (11% versus 9%), death (10% versus 6%) and adverse events (7% versus 12%). The percentage of patients receiving darbepoetin was 90% in both arms.
QoL assessments
Baseline QoL assessments were available from 89 (99%) in the CG arm and 88 (97%) in the CP arm. QoL data at week 18 were available from 50 patients receiving CG and 44 patients receiving CP. There was no difference in the change in global QoL scores (from baseline to week 18) between both arms nor at week 12. The number of QoL responders did not differ significantly between the CG and CP arms at the end of treatment [n = 7 (8%) and n = 9 (10%) responders, respectively] nor at week 18 [n = 11 (12%) and n = 4 (5%) responders, respectively].
The baseline global QoL was lower in patients not completing week 18 questionnaires than those completing week 18 questionnaires (P = 0.001). The mixed-effects model indicated that global QoL scores were lower for patients with worse baseline PS scores (P = 0.001) and for patients with lower baseline global QoL scores (P < 0.001). There were no associations between the global QoL and treatment, age, gender, pretreatment weight loss or extent of disease. There were also no significant interactions between QoL scores and treatment.
toxicity and serious adverse events
Overall, 177 patients were evaluable for toxicity. Grade 3/4 toxic effects occurred in 75% of the patients in the CG and 60% in the CP arm (Table 2) . More myelosuppression and fatique were observed in the CG arm. Neurological toxicity ‡grade 2 occurred more frequently in the CP than in the CG arm (neurosensory 19% versus 5%, P = 0.002; neuromotory: 10% versus 2%, P = 0.03). In both arms, 25% of the patients experienced neuropsychiatric toxicity ‡ CTC grade 2. Alopecia grade 2 was observed in 7% and 37% of the patients in the CG and CP arm, respectively.
comprehensive geriatric assessments
The completion rate of the CGA questionnaires at baseline was 98%. Baseline CGA data are shown in supplemental Table S2 (available at Annals of Oncology online). Both groups were well balanced for all domains and assessments. Percentage of patients with two or more comorbidities was 38% in the CG and 25% in the CP arm not significant (NS). Almost half of patients had limitations in IADL, and more than a quarter had abnormal depression scores. Baseline deficits in emotional functioning (QLQ-C30), role functioning (QLQ-C30) or GDS scores were more likely to experience > grade 2 neuropsychiatric toxic effects. There were no significant interactions between CGA scores and treatment.
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MGAs during and after chemotherapy
No significant trends were observed with MGA in the QoL domains and symptoms during and after chemotherapy between both treatment arms at 12 and 18 weeks. The one exception being physical functioning, which was higher in the CG arm at week 18. A mixed-effects analysis indicated that there was no difference in physical functioning between arms over the treatment period and up until week 18. A summary of MGA per treatment arm during and after treatment until week 18 is given in supplemental Tables S3, S4 and S5 (available at Annals of Oncology online).
tumor response, survival and quality-adjusted survival
In the CG and CP arms, 82% and 75% of the patients were evaluable for tumor response. Overall objective (and confirmed) response rate was 27% in the CG and 19% in the CP arm (NS), the best reported response rate (confirmed and nonconfirmed) 42% and 36%, respectively (NS). Progressive disease during treatment occurred in 9% and 8% of patients in the CG and CP arm, respectively. Cause of death was PD in 89% of the patients and was treatment related in only three patients: two in the CG arm and one in the CP arm. The univariate associations with overall survival of performance score, the baseline QoL and CGA scores and PS are listed in Table 3 and examples of survival curves given in Figure 3 . The PC analysis indicated a dominant component that explained more than three times the variance of the next largest component ( Figure 4A ). Although survival data were not used in the construction of PCs, the first PC was highly prognostic [HR = 0.62 (0.50-0.77); P < 0.0001; Figure 4B ]. Although the four largest contributions to this dominant PC were GFI, physical, role and GDS, it is of note that the contributions of all QoL and CGA items and PS were roughly similar (Table 3 ). The possible relationship of the baseline CGA and QoL scores with five toxicity end points (completing all cycles, the occurrence of ‡grade 3 toxic effects, the occurrence of serious adverse events, the occurrence of ‡grade 2 neurological toxicity and the occurrence of ‡grade 2 psychiatric toxicity) was investigated in separate logistic regression models in each case adjusting for age, gender and extent of disease. Patients with better ADL, IADL or physical functioning (QLQ-C30) scores were more likely to finish all chemotherapy cycles. Patients with worse emotional functioning (QLQ-C30), role functioning (QLQ-C30) or GDS scores were more likely to experience ‡grade 2 psychiatric toxic effects. On the other hand, none of the CGA or QoL summary scores were associated with the other three toxicity end points at the 0.01 significance level.
utilization of health-care resources and hospital setting
Chemotherapy was administered on an outpatient basis. The percentage of patients who were hospitalized during treatment was 37% in the CG arm and 27% in the CP arm (NS). Values are given as n (%), unless and otherwise specified. original article
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The mean total number of nights in hospital over all cycles was 3.4 (range in the CG arm and 1.7 (range 1-15) in the CP arm per patient (P = 0.05).
discussion
This study is the first randomized phase III study that compares two platinum-based chemotherapy schedules in elderly NSCLC patients with QoL as the primary end point. Several trials have studied QoL in elderly NSCLC patients treated with single agents or nonplatinum-containing regimens. In the ELVIS study, patients treated with vinorelbine maintained a better QoL compared with those on best supportive care alone [11] . In the MILES study, QoL was similar for the three treatment arms (vinorelbine, gemcitabine and both drugs combined), changes in QoL scores were not 
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reported [14] . Combination chemotherapy offers a better response rate, failure-free survival and a trend in a better overall survival in the elderly without clear QoL differences [7, 8, 9] . Recently, in the IFCT-0501 study presented by Quoix et al. [34] at ASCO 2010, 451 elderly patients with advanced non-smallcell lung cancer were randomized who were treated with weekly paclitaxel combined with monthly carboplatin versus singleagent therapy. In this study, an unusual carboplatin/paclitaxel doublet schedule proved to be better than single-agent gemcitabine or vinorelbine. PFS was better for the doublet, 6.1 versus 3 months. Median survival in 313 patients was also better for the doublet, with a median survival of 10.4 versus 6.2 months for the single-agent drugs. In the IFCT-0501 study, more adenocarcinomas (50% versus 31% in NVALT-3) and women (28% versus 23% in NVALT-3) were included in the doublet arm compared to the NVALT-3 study, MMSE and ADL were almost similar. More neutropenia (54% versus 37%), neutropenic fever (9.6% versus 6%) and toxic deaths (6.6% versus 0%), but less thrombocytopenia (6.3% versus 28%) were observed in the doublet arm in the IFCT-0501 study. Fatigue and neuropathy were similar. Early deaths (deaths within 3 months) were slightly lower in the NVALT-3 study (15% versus 16.7%).
Outcomes in the fit elderly are similar as those observed in younger patients. We anticipated a different QoL during and after treatment in the elderly due to the specific toxicity profiles of paclitaxel and gemcitabine. In this study, however, we could not establish which side-effects attributed to paclitaxel or gemcitabine were rated more severe by elderly patients. During and after treatment, global QoL was maintained in both treatment arms. In the elderly patients with advanced NSCLC, only 10% of patients were QoL responders to carboplatin containing chemotherapy. This effect was too small to be reflected in a better quality-adjusted survival.
Most prominent toxic effects in both arms were myelosuppression and neuropsychiatric toxicity. Anemia was very mild due to standard supportive care with vitamins and iron supplements in all patients, and darbepoetin in 90% of patients.
The disruptive effects of neuropsychiatric toxicity appeared more prevalent in older male patients [7, 35] . The occurrence of neuropsychiatric toxicity was associated with baseline CGA data, although the majority of toxicity end points could not be predicted. In general, we would have preferred more specific tests such as the Fact Anemia and FACT-Neuro questionnaires; however; we had to limit the number of questionnaires and tests for practical reasons.
In both treatment arms, patients with better physical functioning got more chemotherapy and survived longer. One study showed that physical aspects of patient reported health at baseline and during chemotherapy were significant predictors of clinical outcome [36] .
To reduce the problem of multiplicity, given the large number of CGA and QoL items, a PC analysis was undertaken. Before this analysis, we anticipated a handful of dominant components that would be related to the major dimensions measured by the CGA items. Surprisingly, however, only one dimension came to the fore. Given that there is only a singledominant dimension it is perhaps less surprising that this dimension has significant prognostic value. It is possible that this PC comes near to the clinician's assessment of a patient's life expectancy and PS and as such can be a very accurate predictor of survival.
In conclusion, paclitaxel or gemcitabine added to carboplatin for elderly inoperable NSCLC patients did not have a differential effect on global QoL during and after treatment. CGA and QoL items have one dominant underlying dimension, which has significant prognostic value. Physical and role functioning, frailty and depression are the most prominent elements of this underlying structure. 
